Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer. Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. Earlier published data about patients treated...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/1028505 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566670394130432 |
|---|---|
| author | Kirsten Merx Manuel Barreto Miranda Lenka Kellermann Ulrich Mahlknecht Oliver Lange Michael Gonnermann Ralf-Dieter Hofheinz |
| author_facet | Kirsten Merx Manuel Barreto Miranda Lenka Kellermann Ulrich Mahlknecht Oliver Lange Michael Gonnermann Ralf-Dieter Hofheinz |
| author_sort | Kirsten Merx |
| collection | DOAJ |
| description | We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer. Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. Earlier published data about patients treated outside clinical studies showed a relatively low rate of HER2-testing and insufficient test quality. A total of 2,808 patients retrospectively documented in Therapiemonitor® from 2006 to 2013 were analysed regarding treatment intensity and trends in used drugs. Data on HER2-testing and therapies were analysed in two cohorts documented in 2010 and 2011 (1) compared to 2012 and 2013 (2). Treatment intensity increased: 49.3% of patients received at least a triplet in 2013 compared to 10.1% in 2006. In cohort 2 HER2 expression was tested in 79.1% of the cases. Still, in 26.9% testing was not done as requested by guidelines. Good performance status, multiple metastases, age ≤ 65 years, the objective “to prevent progression,” good cognitive capabilities, estimated good compliance, and social integration positively influenced the probability of HER2-testing; comorbidities negatively affected it. Usage of the combination of fluoropyrimidines and cisplatin with trastuzumab declined from 67% in cohort 1 to 50% in cohort 2. |
| format | Article |
| id | doaj-art-42b020bea69746eab21d828f342d9795 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-42b020bea69746eab21d828f342d97952025-02-03T01:03:23ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/10285051028505Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in GermanyKirsten Merx0Manuel Barreto Miranda1Lenka Kellermann2Ulrich Mahlknecht3Oliver Lange4Michael Gonnermann5Ralf-Dieter Hofheinz6TagesTherapieZentrum am Interdisziplinären Tumorzentrum Mannheim und III. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Universität Heidelberg, 68167 Mannheim, GermanyMarienhospital Darmstadt, Klinik für Innere Medizin, 64285 Darmstadt, GermanyOncology Information Service (OIS), 79098 Freiburg, GermanySt. Lukas Klinik, Abteilung für Onkologie und Hämatologie, Ohligs, 42697 Solingen, GermanyGemeinschaftspraxis für Strahlentherapie-Bonn-Rhein-Sieg, Bonn, 53177 Bad Godesberg, GermanyEvangelisches Klinikum Niederrhein gGmbH, 47169 Duisburg, GermanyTagesTherapieZentrum am Interdisziplinären Tumorzentrum Mannheim und III. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Universität Heidelberg, 68167 Mannheim, GermanyWe analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer. Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. Earlier published data about patients treated outside clinical studies showed a relatively low rate of HER2-testing and insufficient test quality. A total of 2,808 patients retrospectively documented in Therapiemonitor® from 2006 to 2013 were analysed regarding treatment intensity and trends in used drugs. Data on HER2-testing and therapies were analysed in two cohorts documented in 2010 and 2011 (1) compared to 2012 and 2013 (2). Treatment intensity increased: 49.3% of patients received at least a triplet in 2013 compared to 10.1% in 2006. In cohort 2 HER2 expression was tested in 79.1% of the cases. Still, in 26.9% testing was not done as requested by guidelines. Good performance status, multiple metastases, age ≤ 65 years, the objective “to prevent progression,” good cognitive capabilities, estimated good compliance, and social integration positively influenced the probability of HER2-testing; comorbidities negatively affected it. Usage of the combination of fluoropyrimidines and cisplatin with trastuzumab declined from 67% in cohort 1 to 50% in cohort 2.http://dx.doi.org/10.1155/2016/1028505 |
| spellingShingle | Kirsten Merx Manuel Barreto Miranda Lenka Kellermann Ulrich Mahlknecht Oliver Lange Michael Gonnermann Ralf-Dieter Hofheinz Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany Gastroenterology Research and Practice |
| title | Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany |
| title_full | Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany |
| title_fullStr | Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany |
| title_full_unstemmed | Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany |
| title_short | Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany |
| title_sort | trastuzumab in esophagogastric cancer her2 testing and treatment reality outside clinical studies in germany |
| url | http://dx.doi.org/10.1155/2016/1028505 |
| work_keys_str_mv | AT kirstenmerx trastuzumabinesophagogastriccancerher2testingandtreatmentrealityoutsideclinicalstudiesingermany AT manuelbarretomiranda trastuzumabinesophagogastriccancerher2testingandtreatmentrealityoutsideclinicalstudiesingermany AT lenkakellermann trastuzumabinesophagogastriccancerher2testingandtreatmentrealityoutsideclinicalstudiesingermany AT ulrichmahlknecht trastuzumabinesophagogastriccancerher2testingandtreatmentrealityoutsideclinicalstudiesingermany AT oliverlange trastuzumabinesophagogastriccancerher2testingandtreatmentrealityoutsideclinicalstudiesingermany AT michaelgonnermann trastuzumabinesophagogastriccancerher2testingandtreatmentrealityoutsideclinicalstudiesingermany AT ralfdieterhofheinz trastuzumabinesophagogastriccancerher2testingandtreatmentrealityoutsideclinicalstudiesingermany |